Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist

• US 7,320,792 B2
• Filed: 10/25/2001
• Issued: 01/22/2008
• Est. Priority Date: 10/25/2000
• Status: Expired due to Fees

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Sugimoto, Masamichi, Akamatsu, Kenichi, Shimaoka, Shin, Nishimoto, Norihiro, Ito, Hiroaki, Yoshizaki, Kazuyuki, Kitamura, Hidetomo, Kishimoto, Tadamitsu
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US10/399,979
• Publication Number:
  US 20040028681A1
• Time in Patent Office: 2,280 Days
• Field of Search: None
• US Class Current: 424/141.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

A preventive and therapeutic agent for psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Claims

1. A method of treating psoriasis comprising administering an effective amount of an antibody against interleukin-6 (IL-6) receptor to a subject in need thereof, wherein said antibody is monoclonal antibody PM-1 against human IL-6 receptor.

2. A method of treating psoriasis comprising administering an effective amount of an antibody against interleukin-6 (IL-6) receptor to a subject in need thereof, wherein said antibody is monoclonal antibody MR16-1 against mouse IL-6 receptor.

3. A method of treating psoriasis comprising administering an effective amount of an antibody against interleukin-6 (IL-6) receptor to a subject in need thereof, wherein said antibody is a humanized PM-1 antibody.